Oral Minoxidil Manufacturing, Supply & Shortage History

Commercial Tablets and Hair-Loss Prescriptions

The current US tablet label describes 2.5 mg and 10 mg minoxidil tablets for resistant hypertension [2]. A commercial tablet's approved indication is different from a clinician using oral minoxidil for hair loss.

For a prescription, the strength and formulation are important details. A 2.5 mg tablet, a 10 mg tablet and a separately prepared lower-dose capsule are not interchangeable descriptions of the same dispensed product. A change in supply should be handled using the actual prescription rather than an assumed equivalent regimen.

The brand's historical origins do not establish which manufacturer supplies a particular bottle now. The product label, manufacturer and identifying code provide more useful information about the item being dispensed.

What the Verified Shortage Bulletin Says

ASHP's oral-minoxidil bulletin identifies the 2.5 mg strength. Its November 26, 2025 update listed Sun, Par and Teva products as available. It also stated that 10 mg tablets were not affected [1].

The record was created in November 2023. That is the beginning of this particular bulletin, not proof of the first shortage in all minoxidil history. It does not substantiate a separate claim that the FDA first listed a minoxidil shortage in 2020, followed by documented recurrences in 2022 and 2024.

The current bulletin lists product availability, but it does not quantify nationwide alopecia prescriptions or establish how much off-label prescribing contributed to the episode.

Why National Reports and Pharmacy Stock Differ

A shortage report summarizes a market-level situation at a stated time. A pharmacy's stock reflects its own ordering arrangements and recent dispensing. A medicine can be obtainable nationally while a particular location is waiting for replenishment.

The FDA explains that shortages can arise from manufacturing and quality problems, delays and discontinuations [3]. A general explanation of those causes should not be attached to a specific manufacturer or minoxidil episode without product-specific evidence.

When comparing reports, check the publication date, strength, listed products and whether the report concerns shortage, back order or current availability. A generic drug-shortage homepage is not evidence for a detailed minoxidil timeline.

What Does Hair-Loss Research Tell Us About Demand?

Clinical studies demonstrate interest in oral treatment, but their enrollment does not measure national prescription growth. Sinclair's 2018 pilot involved 100 women receiving minoxidil with spironolactone [4]. It was not a 1,404-person minoxidil supply study.

The later 1,404-patient report was a retrospective safety cohort [5]. It describes treatment observations, not the share of all US prescriptions filled by commercial or compounding pharmacies.

These studies therefore should not be used to calculate a 352% increase in national alopecia prescribing, the volume of compounded prescriptions, or a manufacturer's production forecast. Such figures need a dispensing dataset with a stated population and method.

Commercial Tablets and Compounded Formulations

Compounded formulations may be used to provide a prescribed strength or combination. The 2025 international consensus identified the use of compounded oral minoxidil as an area requiring additional research [6]. Evidence for a commercial-tablet regimen should not automatically be described as a bioequivalence study of every compounded capsule.

For a formulation comparison, the relevant details are the active ingredient, intended dose, preparation and evidence about that particular product. A generic registration claim does not answer whether a capsule has been tested for potency or stability.

Likewise, statements that all nonsterile capsules are sterility-tested, that every preparation has proven bioequivalence, or that a general compounding statistic measures oral-minoxidil quality require product-specific support.

What to Check When Supply Changes

Identify the prescribed strength and the exact product the pharmacy is trying to obtain. Ask whether another manufacturer of that same prescribed product is available, and whether the delay concerns the local wholesaler or a broader shortage.

A different tablet strength or formulation can require a different dispensing arrangement. Availability of 10 mg tablets does not establish that changing a 2.5 mg prescription is appropriate.

Prices and lead times should come from an actual current quote. The cited shortage record does not establish a universal monthly price, delivery date, or need for a 90-day reserve. A dated source is most useful when its limits remain visible.